Brought to you by 
Tarveda pens agreement for Madrigal's HSP90 drug conjugate program
20 Sep 2016
Executive Summary
Tarveda Therapeutics Inc. licensed exclusive global rights to Madrigal Pharmaceuticals Inc.'s HSP90 drug conjugate program for oncology drug development. The deal includes lead compound PEN866.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tarveda pens agreement for Madrigal's HSP90 drug conjugate program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice